Jacqueline V. Aredo

2.0k total citations · 1 hit paper
37 papers, 974 citations indexed

About

Jacqueline V. Aredo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Jacqueline V. Aredo has authored 37 papers receiving a total of 974 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Jacqueline V. Aredo's work include Lung Cancer Treatments and Mutations (29 papers), Lung Cancer Diagnosis and Treatment (15 papers) and Lung Cancer Research Studies (11 papers). Jacqueline V. Aredo is often cited by papers focused on Lung Cancer Treatments and Mutations (29 papers), Lung Cancer Diagnosis and Treatment (15 papers) and Lung Cancer Research Studies (11 papers). Jacqueline V. Aredo collaborates with scholars based in United States, Canada and Netherlands. Jacqueline V. Aredo's co-authors include Jay Shah, Siddhartha Sikdar, Lynn H. Gerber, Juliana Heimur, Heather A. Wakelee, Joel W. Neal, Sukhmani K. Padda, Barbara I. Karp, Pamela Stratton and Katrina Heyrana and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Jacqueline V. Aredo

34 papers receiving 948 citations

Hit Papers

Myofascial Trigger Points Then and Now: A Historical and ... 2015 2026 2018 2022 2015 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Myofascial Trigger Points Then and Now: A Historical and Scientific Perspective
    2015 281 citations Jay Shah, Juliana Heimur et al. PM&R profile →

Peers

Jacqueline V. Aredo
Ying-hao SUN China
Jean M. Hansen United States
Madhu P. Menon United States
Cristina Ferrario Italy
Jianing Miao China
Craig C. Teerlink United States
Lihong Li China
Nicholas R Hoyle United Kingdom
Wei Yuan China
Leeaht Gross United States
Ying-hao SUN China
Jacqueline V. Aredo
Citations per year, relative to Jacqueline V. Aredo Jacqueline V. Aredo (= 1×) peers Ying-hao SUN

Countries citing papers authored by Jacqueline V. Aredo

Since Specialization
Citations

This map shows the geographic impact of Jacqueline V. Aredo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacqueline V. Aredo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacqueline V. Aredo more than expected).

Fields of papers citing papers by Jacqueline V. Aredo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacqueline V. Aredo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacqueline V. Aredo. The network helps show where Jacqueline V. Aredo may publish in the future.

Co-authorship network of co-authors of Jacqueline V. Aredo

This figure shows the co-authorship network connecting the top 25 collaborators of Jacqueline V. Aredo. A scholar is included among the top collaborators of Jacqueline V. Aredo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacqueline V. Aredo. Jacqueline V. Aredo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Aredo, Jacqueline V., Heather A. Wakelee, Kavitha Ramchandran, et al.. (2024). Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC. JTO Clinical and Research Reports. 5(12). 100741–100741. 1 indexed citations
3.
Adderley, Helen, J. Searle, L Wilson, et al.. (2023). 2253P RAS-precision medicine trans-atlantic partnership: Comparative analysis of KRAS codon 12 and 13 mutations in non-small cell lung cancer. Annals of Oncology. 34. S1159–S1160.
4.
Choi, Eunji, Sophia J. Luo, Victoria Y. Ding, et al.. (2023). Risk model‐based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model. Cancer. 130(5). 770–780. 3 indexed citations
5.
Choi, Eunji, Julie Wu, Jacqueline V. Aredo, et al.. (2023). Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked. JAMA Network Open. 6(11). e2343278–e2343278. 6 indexed citations
6.
Aredo, Jacqueline V., Eunji Choi, Victoria Y. Ding, et al.. (2022). Racial and Ethnic Disparities in Lung Cancer Screening by the 2021 USPSTF Guidelines Versus Risk-Based Criteria: The Multiethnic Cohort Study. JNCI Cancer Spectrum. 6(3). 23 indexed citations
7.
Aredo, Jacqueline V., Heather A. Wakelee, Angela Bik‐Yu Hui, et al.. (2022). Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer. Cancer Treatment and Research Communications. 33. 100659–100659. 3 indexed citations
8.
Choi, Eunji, Nilotpal Sanyal, Victoria Y. Ding, et al.. (2021). Development and Validation of a Risk Prediction Model for Second Primary Lung Cancer. JNCI Journal of the National Cancer Institute. 114(1). 87–96. 13 indexed citations
9.
Aredo, Jacqueline V., Natasha Purington, Li Su, et al.. (2021). Metabolomic profiling for second primary lung cancer: A pilot case-control study. Lung Cancer. 155. 61–67. 11 indexed citations
10.
Choi, Eunji, Sophia J. Luo, Jacqueline V. Aredo, et al.. (2021). The Survival Impact of Second Primary Lung Cancer in Patients With Lung Cancer. JNCI Journal of the National Cancer Institute. 114(4). 618–625. 19 indexed citations
11.
Luo, Sophia J., Eunji Choi, Jacqueline V. Aredo, et al.. (2021). Smoking Cessation After Lung Cancer Diagnosis and the Risk of Second Primary Lung Cancer: The Multiethnic Cohort Study. JNCI Cancer Spectrum. 5(5). 5 indexed citations
12.
Aredo, Jacqueline V., Heather A. Wakelee, Joel W. Neal, & Sukhmani K. Padda. (2021). Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer. Cancer Treatment and Research Communications. 30. 100497–100497. 7 indexed citations
13.
Aredo, Jacqueline V., Jessica A. Hellyer, Joel W. Neal, et al.. (2021). MO01.01 Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy. Journal of Thoracic Oncology. 16(1). S15–S15. 1 indexed citations
14.
Aredo, Jacqueline V., Sukhmani K. Padda, Kavitha Ramchandran, et al.. (2021). EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy. Clinical Lung Cancer. 23(2). e148–e153. 20 indexed citations
15.
Aredo, Jacqueline V., Isa Mambetsariev, Jessica A. Hellyer, et al.. (2021). Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. Journal of Thoracic Oncology. 16(6). 1030–1041. 86 indexed citations
16.
Hellyer, Jessica A., Jacqueline V. Aredo, Millie Das, et al.. (2021). Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC. Journal of Thoracic Oncology. 16(5). 868–872. 43 indexed citations
17.
Aredo, Jacqueline V., Maximilian Diehn, Gerald J. Berry, & Heather A. Wakelee. (2020). Targeted Treatment of Multiple Primary Lung Cancers Harboring Distinct EGFR or RET Alterations: A Case Report. Clinical Lung Cancer. 22(5). e673–e677. 3 indexed citations
18.
19.
Aredo, Jacqueline V., Sukhmani K. Padda, Christian A. Kunder, Summer S. Han, & Heather A. Wakelee. (2019). OA03.07 Evaluating Racial Differences in KRAS-Mutant Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(11). S1133–S1133. 1 indexed citations
20.
Shah, Jay, et al.. (2015). Myofascial Trigger Points Then and Now: A Historical and Scientific Perspective. PM&R. 7(7). 746–761. 281 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ying-hao SUN Breakdown of academic impact, for papers by Jean M. Hansen Breakdown of academic impact, for papers by Madhu P. Menon Breakdown of academic impact, for papers by Cristina Ferrario Breakdown of academic impact, for papers by Jianing Miao Breakdown of academic impact, for papers by Craig C. Teerlink Breakdown of academic impact, for papers by Lihong Li Breakdown of academic impact, for papers by Nicholas R Hoyle Breakdown of academic impact, for papers by Wei Yuan Breakdown of academic impact, for papers by Leeaht Gross
Rankless by CCL
2026